NEW YORK, Oct. 27, 2020 /PRNewswire/ -- Oramed
Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com),
a clinical-stage pharmaceutical company focused on the development
of oral drug delivery systems, announced today that CEO
Nadav Kidron will join Premas
Biotech's Co-Founder and Managing Director Dr. Prabuddha Kundu in a webinar titled "The Journey
of Oral Insulin: Oramed Story" on Wednesday
October 28, 2020 at 9:00 am
ET. Investors are invited to register for the webinar at:
https://zoom.us/webinar/register/WN_63tKqgu9Rcq8ON2cwcKg_w?timezone_id=America%2FNew_York
Throughout history, oral administration has been regarded as the
most convenient mode of drug delivery, as it requires minimal
expertise and invasiveness. Although oral delivery works well for
small-molecule drugs, oral delivery of macromolecules (particularly
proteins and peptides) has been limited by acidic conditions in the
stomach and low permeability across the intestinal epithelium.
Oramed has made tremendous strides in the oral delivery of
proteins and peptides, beginning with its oral insulin capsule
ORMD-0801 which is entering pivotal Phase 3 trials in the U.S.
On Wednesday at 9 am ET, in the
first part of a two-part webinar series, the session will focus on
the journey of Oral Insulin - from concept to a successful Phase 3
candidate.
About Oramed Pharmaceuticals
Oramed Pharmaceuticals is a platform technology pioneer in
the field of oral delivery solutions for drugs currently delivered
via injection. Established in 2006, with offices in New
York and Israel, Oramed has developed a novel Protein
Oral Delivery (POD™) technology. Oramed is seeking to revolutionize
the treatment of diabetes through its proprietary lead
candidate, ORMD-0801, which has the potential to be the first
commercial oral insulin capsule for the treatment of
diabetes. The Company has completed multiple Phase II clinical
trials under an Investigational New Drug application with
the U.S. Food and Drug Administration. In addition, Oramed is
developing an oral GLP-1 (Glucagon-like peptide-1) analog
capsule, ORMD-0901.
For more information, please visit www.oramed.com.
Forward-looking statements: This press release
contains forward-looking statements. For example, we are using
forward-looking statements when we discuss the potential of
ORMD-0801 to be the first commercial oral insulin capsule for the
treatment of diabetes or revolutionizing the treatment of diabetes
with our products. In addition, historic results of scientific
research and clinical trials do not guarantee that the conclusions
of future research or trials will suggest identical or even similar
conclusions. These forward-looking statements are based on the
current expectations of the management of Oramed only, and are
subject to a number of factors and uncertainties that could cause
actual results to differ materially from those described in the
forward-looking statements, including the risks and uncertainties
related to the progress, timing, cost, and results of clinical
trials and product development programs; difficulties or delays in
obtaining regulatory approval or patent protection for our product
candidates; competition from other pharmaceutical or biotechnology
companies; and our ability to obtain additional funding required to
conduct our research, development and commercialization activities.
In addition, the following factors, among others, could cause
actual results to differ materially from those described in the
forward-looking statements: changes in technology and market
requirements; delays or obstacles in launching our clinical trials;
changes in legislation; inability to timely develop and introduce
new technologies, products and applications; lack of validation of
our technology as we progress further and lack of acceptance of our
methods by the scientific community; inability to retain or attract
key employees whose knowledge is essential to the development of
our products; unforeseen scientific difficulties that may develop
with our process; greater cost of final product than anticipated;
loss of market share and pressure on pricing resulting from
competition; laboratory results that do not translate to equally
good results in real settings; our patents may not be sufficient;
and finally that products may harm recipients, all of which could
cause the actual results or performance of Oramed to differ
materially from those contemplated in such forward-looking
statements. Except as otherwise required by law, Oramed undertakes
no obligation to publicly release any revisions to these
forward-looking statements to reflect events or circumstances after
the date hereof or to reflect the occurrence of unanticipated
events. For a more detailed description of the risks and
uncertainties affecting Oramed, reference is made to Oramed's
reports filed from time to time with the Securities and Exchange
Commission.
Company Contact
Estee
Yaari
+1-844-9-ORAMED
estee@oramed.com
View original
content:http://www.prnewswire.com/news-releases/oramed-ceo-nadav-kidron--premas-biotech-to-host-webinar-the-journey-of-oral-insulin-oramed-story-on-wednesday-october-28-2020-301160530.html
SOURCE Oramed Pharmaceuticals Inc.